GAT Sport Releases a New, Truly Delicious Plant-Based Protein — GAT PLANT PROTEIN

GAT Sport Releases a New, Truly Delicious Plant-Based Protein — GAT PLANT PROTEINGAT Sport is delighted to announce its new, gourmet flavored PLANT PROTEIN. This all-new plant-based, quad-blend of vegan-sourced proteins has a surprise distinction: It’s really delicious compared to typical earthy, chalky-tasting plant protein powders. Some say it’s mouthwatering.

GAT Sport Releases a New, Truly Delicious Plant-Based Protein — GAT PLANT PROTEIN
Plant Protein – by GAT Sport

The taste and texture experience of GAT Sport Plant Protein’s mouthwatering gourmet flavors are the real deal. Unlike other unappealingly earthy plant-based proteins, GAT Plant Protein satisfies even the most discerning taste buds.

MONROE, Conn. – January 13, 2023 – (Newswire.com)

GAT Sport Plant Protein has four gourmet flavors quite unlike other unappealingly earthy plant-based proteins. Plus, it’s the real deal: gluten-free, dairy/lactose-free, and has no artificial flavors or dyes.

GAT Sport President & CEO Charles Moser made the announcement, “GAT Plant Protein satisfies even the most discerning taste buds. The flavors are fantastic. We’ve designed it to be the favorite of high-level competitive athletes and for anyone seeking a delicious, animal-free/dairy-free protein source. And, with just minimal carbs, sugar, and fat content, it’s a perfect fit for fitness. GAT Sport is constantly redefining itself to meet and exceed expectations. We’re proud to offer our global customers these delicious, high-quality products.”

GAT Sport Plant Protein is a uniquely clean, plant-sourced “quad-blend” formula. It provides 20g of protein in a low-fat formula to indulge in daily. Its best-in-class flavors are fortified from agave inulin. Plus, they’re soy and cholesterol free, are NON-GMO, Kosher Dairy certified, and the Pancakes & Syrup variety is Halal Certified. They can be used in baking with great-looking, great-tasting results.

Plus, GAT Sport Plant Protein is easily stackable with other GAT products, a feature that GAT customers request and expect. Use it with Nitraflex® Pre-Workouts, FLEXX EAAs™ Intra-Workouts, GAT Essentials Vitamins & Minerals, and with GAT Jetfuel® thermogenic fat-burners.

About GAT Sport

Charles Moser, President & CEO, has over 25 years’ experience in training and supplementation formulation, design and marketing. Under his leadership, GAT Sport creates forward-looking products that propel athletes worldwide, and in the industry. Designing with clinically researched ingredients and university studies, he produces and markets clinically tested, efficaciously-dosed formulas that become legendary. Charles is diversifying this highly respected global brand with high-energy workout products and those for repair and recovery after training, plus general health & fitness. He drives TeamGAT to compete harder every day and on every level. Follow Charles on Instagram @GAT_CEO_Charles_Moser.

facebook.com/gatsupplements          221.6k Followers
instagram.com/gatsupplements        183k Followers
https://twitter.com/gatsportusa        6.8k Followers

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact Information:

Marshall Post

Director of Marketing
[email protected]

(888) 811-4286

Press Release Service
by
Newswire.com

Original Source:

GAT Sport Releases a New, Truly Delicious Plant-Based Protein — GAT PLANT PROTEIN

USA News (USANews.com) Plans to Quickly Reach Over a Hundred Million People

USA News (USANews.com) Plans to Quickly Reach Over a Hundred Million PeopleThey are doing this through their Verified News Influencer Program

USA News (USANews.com) Plans to Quickly Reach Over a Hundred Million People
USANews.com’s Influencer Voices Page

USANews.com’s Influencer Voices Page

HOUSTON – January 13, 2023 – (Newswire.com)

Newly launched media platform USA News (USANews.com) is already garnering tens of thousands of new visitors by the day and doesn’t plan on slowing down. Gallant Dill, CEO of USA News, has implemented a program called “Verified News Influencers“, where they build a partnership with super influencers and allow them to post updates in story form that they can share all over social media.

Within USANews.com‘s first 30 days of launching, the Verified News Influencer program has already signed up over 100 famous influencers with over 100,000,000 in potential reach. They plan on bringing in over 1,000 more by the middle of the year with a goal to reach a billion eyes by 2024.

“My goal for USANews.com is for it to be the biggest news site in America, and achieving this in the shortest amount of time through viral marketing tactics and pre-existing relationships.” – Gallant Dill

To check out the latest updates on USA News, visit the website at USANews.com or email [email protected]

More about USA News (USANews.com

USANews.com is a media platform that shares non-political and non-biased media. USA News delivers the most viral content on the web and gives a positive voice back to the people.

Contact Information:

Jessica Williams

Media Journalist
[email protected]

Press Release Service
by
Newswire.com

Original Source:

USA News (USANews.com) Plans to Quickly Reach Over a Hundred Million People

Hype Hair Acquires Good Good Hair, Adds E-Commerce & Industry Veteran

Hype Hair Acquires Good Good Hair, Adds E-Commerce & Industry VeteranHype Hair’s CEO Lia Dias making strategic moves to bring Hype Hair back to prominence

LOS ANGELES – January 13, 2023 – (Newswire.com)

One year after acquiring Hype Hair magazine and celebrating its 30-year anniversary, beauty mogul Lia Dias has made another acquisition (GoodGoodHair) and added an industry veteran and partner (Dennis McKinley, Detroit Equities) as she focuses on continuing to diversify the Hype Hair revenue model and scaling Hype Hair internationally via e-commerce, licensing, franchising and video/podcast content.

The magazine, which was founded in 1992 by Belinda Trotter, has always been the industry leader in all things hair for women of color, with the superstars Beyoncé, Ciara, Rihanna, Erykah Badu, Nia Long, Trina and more all gracing its cover. 

“We intend to continue Hype Hair’s long tradition of providing a platform to tell stories, provide education, news, and visual content to women of color all over the world while adding product via e-commerce and licensing which in turn provides the same content we seek back to us via the HH community,” said Lia Dias. 

Hype Hair also announces a partnership as an official media partner with Bronner Bros, the largest professional trade show dedicated to multicultural beauty and licensing deals with conglomerate Conair. 

Hype Hair will add an Atlanta satellite office and maintain its headquarters in Los Angeles, California.

Terms of The Good Good Hair acquisition will not be disclosed.

About Hype Hair 

Hype Hair is the premier source for the latest in Black hair and beauty trends, products, and hairstyles. Lia Dias will continue to serve as CEO and Dennis McKinley will join the board and spearhead licensing and e-commerce.

Contact Information:

Ashli johnson

press
[email protected]

6783622394

Press Release Service
by
Newswire.com

Original Source:

Hype Hair Acquires Good Good Hair, Adds E-Commerce & Industry Veteran

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory BoardThe appointment further strengthens the company’s scientific resources, including in neuronal function and synaptic transmission, which are central to Neurocentria’s approach for developing novel therapies for neurodegenerative and neuropsychiatric disorders.

WALNUT CREEK, Calif. – January 13, 2023 – (Newswire.com)

Neurocentria, Inc., a privately held late-stage biotechnology company developing novel therapies for neurodegenerative and neuropsychiatric disorders, has today announced that Dr. Thomas Südhof, Avram Goldstein Professor in Stanford University School of Medicine and an investigator of the Howard Hughes Medical Institute, has joined the company’s Scientific Advisory Board (SAB).

Dr. Südhof’s appointment further strengthens the company’s scientific resources, in line with the commitment to develop unique therapies for individuals with neurodegenerative and neuropsychiatric disorders.

Dr. Südhof will become the SAB’s third expert advisor alongside Dr. Jack Feldman, Distinguished Professor of Neurobiology at the University of California, Los Angeles, and Dr. Thomas Laughren, Former Director of the Division of Psychiatry Products, Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.

On joining the SAB, Dr. Südhof will support the Company’s leadership in its oversight and scrutiny of the Company’s research and clinical development strategies. The SAB provides general technical guidance, particularly in relation to potential research and clinical development-related transactions.

Dr. Südhof brings unique experience in the field of neuronal function and synaptic transmission, which are central to Neurocentria’s approach for developing novel therapies for neurodegenerative and neuropsychiatric disorders. Dr. Südhof won the Nobel Prize in Physiology or Medicine (shared with James Rothman and Randy Sheckman) in 2013 for his discoveries of machinery regulating vesicle traffic, a major transport system in our cells, a mechanism critical for synaptic transmission. He also brings extensive experience in business strategy through his roles as a member of the Board of Directors at Sanofi S.A., one of the world’s largest pharmaceutical and healthcare companies, and an Independent Director of CytoDel Inc.

Commenting on the appointment, Dr. Guosong Liu, Chairman and CEO of Neurocentria, said: “I am delighted to welcome Tom to Neurocentria. Our current leading drug candidate was designed based on scientific discoveries related to fundamental synaptic physiology. Tom’s expertise in synaptic structure and its function means he is perfectly placed to provide the insight and challenge we need as Neurocentria moves further into developing next-generation medicines for treating neurological disorders.”

Biography

Dr. Südhof began his independent career in 1986 at UT Southwestern, where he stayed until 2008 and, among others, was the founding chair of the Department of Neuroscience. In 2008, Dr. Südhof moved to Stanford University and became the Avram Goldstein Professor in the School of Medicine. In addition, Dr. Südhof has been an Investigator of the Howard Hughes Medical Institute since 1986.

Prior to becoming a neuroscientist, Dr. Südhof was trained in the biophysics of subcellular organelles at the Max-Planck-Institut für biophysikalische Chemie and in cholesterol metabolism at UT Southwestern. When Dr. Südhof started his laboratory, he decided to switch to neuroscience to study synapses because of their central, as yet incompletely understood role in brain function. Dr. Südhof’s work initially focused on the mechanism of neurotransmitter release, which is the first step in synaptic transmission that accounts for the speed and precision of information transfer in the brain. It was for this work that Dr. Südhof was awarded in 2013 the Albert Lasker Basic Medical Research Award (with Richard Scheller) and the Nobel Prize in Physiology or Medicine (with James Rothman and Randy Schekman). In the last decade, Dr. Südhof’s research emphasis has switched to focus on a different unsolved problem in neuroscience that regards synapses, namely how synapses are established specifically between defined pre- and postsynaptic neurons, and how such connections are endowed with specific properties by these neurons. Addressing this fundamental question is essential for understanding how circuits are wired and how they process information, but the basic rules that govern synapse formation and specification are only now beginning to emerge. Elucidating these rules is the goal of Dr. Südhof’s present work.

About Neurocentria

Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders. For further information, please visit www.neurocentria.com/about.

Cautionary statement regarding forward-looking statements

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of our drug candidates, including NRCT-101SR, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; the effects of the outbreak of COVID-19 on our business and results of operations; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for our programs to continue to develop; our ability to protect our intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect our products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Guy Bar-Klein

Director of Research

[email protected]

+1 (925) 954-4868

Related Files
Sudhof SAB_final.pdf

Press Release Service
by
Newswire.com

Original Source:

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory BoardThe appointment further strengthens the company’s scientific resources, including in neuronal function and synaptic transmission, which are central to Neurocentria’s approach for developing novel therapies for neurodegenerative and neuropsychiatric disorders.

WALNUT CREEK, Calif. – January 13, 2023 – (Newswire.com)

Neurocentria, Inc., a privately held late-stage biotechnology company developing novel therapies for neurodegenerative and neuropsychiatric disorders, has today announced that Dr. Thomas Südhof, Avram Goldstein Professor in Stanford University School of Medicine and an investigator of the Howard Hughes Medical Institute, has joined the company’s Scientific Advisory Board (SAB).

Dr. Südhof’s appointment further strengthens the company’s scientific resources, in line with the commitment to develop unique therapies for individuals with neurodegenerative and neuropsychiatric disorders.

Dr. Südhof will become the SAB’s third expert advisor alongside Dr. Jack Feldman, Distinguished Professor of Neurobiology at the University of California, Los Angeles, and Dr. Thomas Laughren, Former Director of the Division of Psychiatry Products, Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.

On joining the SAB, Dr. Südhof will support the Company’s leadership in its oversight and scrutiny of the Company’s research and clinical development strategies. The SAB provides general technical guidance, particularly in relation to potential research and clinical development-related transactions.

Dr. Südhof brings unique experience in the field of neuronal function and synaptic transmission, which are central to Neurocentria’s approach for developing novel therapies for neurodegenerative and neuropsychiatric disorders. Dr. Südhof won the Nobel Prize in Physiology or Medicine (shared with James Rothman and Randy Sheckman) in 2013 for his discoveries of machinery regulating vesicle traffic, a major transport system in our cells, a mechanism critical for synaptic transmission. He also brings extensive experience in business strategy through his roles as a member of the Board of Directors at Sanofi S.A., one of the world’s largest pharmaceutical and healthcare companies, and an Independent Director of CytoDel Inc.

Commenting on the appointment, Dr. Guosong Liu, Chairman and CEO of Neurocentria, said: “I am delighted to welcome Tom to Neurocentria. Our current leading drug candidate was designed based on scientific discoveries related to fundamental synaptic physiology. Tom’s expertise in synaptic structure and its function means he is perfectly placed to provide the insight and challenge we need as Neurocentria moves further into developing next-generation medicines for treating neurological disorders.”

Biography

Dr. Südhof began his independent career in 1986 at UT Southwestern, where he stayed until 2008 and, among others, was the founding chair of the Department of Neuroscience. In 2008, Dr. Südhof moved to Stanford University and became the Avram Goldstein Professor in the School of Medicine. In addition, Dr. Südhof has been an Investigator of the Howard Hughes Medical Institute since 1986.

Prior to becoming a neuroscientist, Dr. Südhof was trained in the biophysics of subcellular organelles at the Max-Planck-Institut für biophysikalische Chemie and in cholesterol metabolism at UT Southwestern. When Dr. Südhof started his laboratory, he decided to switch to neuroscience to study synapses because of their central, as yet incompletely understood role in brain function. Dr. Südhof’s work initially focused on the mechanism of neurotransmitter release, which is the first step in synaptic transmission that accounts for the speed and precision of information transfer in the brain. It was for this work that Dr. Südhof was awarded in 2013 the Albert Lasker Basic Medical Research Award (with Richard Scheller) and the Nobel Prize in Physiology or Medicine (with James Rothman and Randy Schekman). In the last decade, Dr. Südhof’s research emphasis has switched to focus on a different unsolved problem in neuroscience that regards synapses, namely how synapses are established specifically between defined pre- and postsynaptic neurons, and how such connections are endowed with specific properties by these neurons. Addressing this fundamental question is essential for understanding how circuits are wired and how they process information, but the basic rules that govern synapse formation and specification are only now beginning to emerge. Elucidating these rules is the goal of Dr. Südhof’s present work.

About Neurocentria

Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders. For further information, please visit www.neurocentria.com/about.

Cautionary statement regarding forward-looking statements

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of our drug candidates, including NRCT-101SR, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; the effects of the outbreak of COVID-19 on our business and results of operations; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for our programs to continue to develop; our ability to protect our intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect our products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Guy Bar-Klein

Director of Research

[email protected]

+1 (925) 954-4868

Related Files
Sudhof SAB_final.pdf

Press Release Service
by
Newswire.com

Original Source:

Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board